https://clinicaltrials.gov/ct2/show/NCT04456673?type=Intr https://clinicaltrials.gov/ct2/show/NCT04456673?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation Condition : Chronic Obstructive Pulmonary Disease Interventions : Drug: Dupilumab SAR231893; Drug: Inhaled Corticosteroid; Drug: Inhaled Long-Acting Beta Agonist; Drug: Inhaled Long-Acting Muscarinic Antagonist; Drug: Placebo Sponsors : Sanofi; Regeneron Pharmaceuticals Recruiting NCT04456673 Thu, 02 Jul 2020 12:00:00 EDT